Adedokun KA, Imodoye SO, Bello IO, Lanihun A, Bello IO. Therapeutic potentials of medicinal plants for the treatment of cancer and significance of computational tools in anticancer drug discovery. In: Egbuna C, Rudrapal M, Tijjani H, editors. Phytochemistry, computational tools, and databases in drug discovery. Amsterdam: Elsevier; 2023.

Google Scholar 

Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imodoye SO, Adedokun KA, Muhammed AO, Bello IO, Muhibi MA, Oduola T, Oyenike MA. Understanding the complex milieu of epithelial-mesenchymal transition in cancer metastasis: new insight into the roles of transcription factors. Front Oncol. 2021;11:762817.

Nieto MA, Cano A. The epithelial–mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol. 2012;22:361–8.

Article  CAS  PubMed  Google Scholar 

Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38:53.

Article  PubMed  PubMed Central  Google Scholar 

Chang R, Zhang Y, Zhang P, Zhou Q. Snail acetylation by histone acetyltransferase p300 in lung cancer. Thorac Cancer. 2017;8:131–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manfioletti G, Fedele M. Epithelial–mesenchymal transition (EMT) 2021. Int J Mol Sci. 2022;23:5848.

Article  PubMed  PubMed Central  Google Scholar 

Galbraith M, Levine H, Onuchic JN, Jia D. Decoding the coupled decision-making of the epithelial-mesenchymal transition and metabolic reprogramming in cancer. iScience. 2023;26(1):105719.

Tan T, Shi P, Abbas MN, Wang Y, Xu J, Chen Y, Cui H. Epigenetic modification regulates tumor progression and metastasis through EMT (review). Int J Oncol. 2022;60:1–17.

Article  Google Scholar 

Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26.

Article  CAS  PubMed  Google Scholar 

Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.

Article  PubMed  PubMed Central  Google Scholar 

Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multitool for tumor progression. EMBO J. 2021;40:e108647.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coghlin C, Murray GI. Current and emerging concepts in tumor metastasis. J Pathol. 2010;222:1–15.

Article  CAS  PubMed  Google Scholar 

Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84.

Article  CAS  PubMed  Google Scholar 

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195–206.

Article  CAS  PubMed  Google Scholar 

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–98.

Article  PubMed  Google Scholar 

Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492–504.

Article  CAS  PubMed  Google Scholar 

Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.

Article  PubMed  Google Scholar 

Zheng H, Kang Y. Multilayer control of the EMT master regulators. Oncogene. 2014;33:1755–63.

Article  CAS  PubMed  Google Scholar 

Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin Cancer Res. 2021;27:4669–79.

Article  CAS  PubMed  Google Scholar 

Romeo E, Caserta CA, Rumio C, Marcucci F. The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system. Cells. 2019;8:460.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn LA, Fousek K, Palena C. Tumor plasticity and resistance to immunotherapy. Trends Cancer. 2020;6:432–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seliger B. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. HLA. 2016;88:213–20.

Article  CAS  PubMed  Google Scholar 

López-Soto A, Huergo-Zapico L, Galván JA, Rodrigo L, de Herreros AG, Astudillo A, Gonzalez S. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol. 2013;190:4408–19.

Article  PubMed  Google Scholar 

Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JYH, Strbenac D, Saw RPM, Thompson JF, Wilmott JS, Scolyer RA, Long GV, Kefford RF, Rizos H. Transcriptional downregulation of MHC class I and melanoma de differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11:1897.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Can Res. 2017;77:3982–9.

Article  CAS  Google Scholar 

Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX-F. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.

Article  CAS  PubMed  Google Scholar 

Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, Weinberg RA. Direct and indirect regulators of epithelial-mesenchymal transition–mediated immunosuppression in breast carcinomas, cancer. Discovery. 2021;11:1286–305.

CAS  Google Scholar 

Chen X-H, Liu Z-C, Zhang G, Wei W, Wang X-X, Wang H, Ke H-P, Zhang F, Wang H-S, Cai S-H, Du J. TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol. 2015;65:34–42.

Article  CAS  PubMed  Google Scholar 

Aguilera TA, Giaccia AJ. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion—a new role for the AXL receptor tyrosine kinase. Clin Cancer Res. 2017;23:2928–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maccalli C, Rasul KI, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of antitumor immune responses. Semin Cancer Biol. 2018;53:189–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022;12:747–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers. 2020;12:1760.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morozov AV, Karpov VL. Proteasomes and several aspects of their heterogeneity relevant to cancer. Front Oncol. 2019;9:761.

Article  PubMed  PubMed Central  Google Scholar 

Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci. 2016;113:E1555–64.

Article  CAS  PubMed  PubMed Central